Литература:

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) report 2022; Available at: http://goldcopd.org, доступ 01.12.2021.
2. Chalmers J.D., Laska I.F., Franssen F.M.E. et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J 2020; 55: 2000351.
3. Nici L., Mammen M.J., Charbek E. et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56‐e69.
4. Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline Published: 5 December 2018 www.nice.org.uk/guidance/ng115, доступ 01.12.2021.
5. Bourbeau J. et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD - 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232.
6. Федеральные клинические рекомендации «Хроническая Обструктивная Болезнь Легких», 2021 год. https://cr.minzdrav.gov.ru/recomend/603_2, доступ 01.12.2021.
7. Chapman K.R. et al. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med 2018; Vol 198, Iss 3, pp 329–339.
8. Magnussen H. et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. N Engl J Med. 2014; 371:1285-1294.
9. Calzetta L. et al. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulmonary Pharmacology & Therapeutics 45 (2017) 148-158.
10. Cazzola M. et al., Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J 2018; 52:1801586.

Заявление о конфликте интересов:

Мероприятие проводилось при спонсорском участии компаний GSK и Chiesi. Конфликт интересов не повлиял на заключение экспертов.